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Background: Recurrent hepatitis C virus infection after liver transplantation is associated with reduced graft and patient
survival. Re-transplantation for graft failure due to recurrent hepatitis C is controversial and not performed in all centers.
Case presentation: We describe a 54-year-old patient with hepatitis C virus genotype 1b infection and a null response to
pegylated interferon-α and ribavirin who developed decompensated graft cirrhosis 6 years after a first liver transplantation.
Treatment with sofosbuvir and ribavirin allowed for rapid negativation of serum HCV RNA and was well tolerated despite
advanced liver and moderate renal dysfunction. Therapeutic drug monitoring did not reveal any clinically significant
drug-drug interactions. Despite virological response, the patient remained severely decompensated and re-transplantation
was performed after 46 days of undetectable serum HCV RNA. The patient is doing well 12 months after his second liver
transplantation and remains free of hepatitis C virus.
Conclusions: The use of directly acting antivirals may allow for successful liver re-transplantation for recipients who remain
decompensated despite virological response and is likely to improve the outcome of liver re-transplantation for end-stage
recurrent hepatitis C.
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Chronic hepatitis C (CHC) represents the leading indica-
tion to liver transplantation (LT) [1-3]. Recurrent hepa-
titis C virus (HCV) infection is universal in patients with
detectable serum HCV RNA at the time of LT, and
20-40% will develop cirrhosis of the liver graft within 5
years after LT [1-3]. Treatment of recurrent HCV infec-
tion has been a challenge, with limited sustained viro-
logical response (SVR) rates and often poor tolerability.
Hence, recurrent hepatitis C is associated with reduced
graft and patient survival [1-3].
Re-transplantation for graft failure due to recurrent
hepatitis C is controversial, and some centers abandoned
the procedure because of poor outcomes [1,4,5]. HCV* Correspondence: Julien.Vionnet@chuv.ch
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re-transplantation, but this was difficult to achieve until
recently.
Outstanding progress has been made in the field of
CHC treatment, with the development of potent directly
acting antivirals (DAAs) [6,7]. These DAAs are expected
to have a major impact on LT for CHC [8,9]. Recently,
Curry et al. have demonstrated that re-infection of a first
liver graft can be prevented by sofosbuvir (SOF; a nucleotide
NS5B polymerase inhibitor) and ribavirin (RBV) in patients
with compensated cirrhosis awaiting LT for hepatocellular
carcinoma due to CHC [10]. Moreover, a seminal case
report has shown the successful treatment of fibrosing cho-
lestatic hepatitis with an oral combination of daclatasvir
(an NS5A inhibitor) and SOF [11], and studies have dem-
onstrated significantly improved SVR rates in patients
treated for recurrent hepatitis C with new DAAs [12,13].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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successful SOF and RBV treatment before liver re-
transplantation for terminal graft failure due to recur-
rent hepatitis C. This treatment regimen allowed for re-
transplantation and successfully prevented re-infection
of the second liver graft.
Case presentation
A 54-year-old Caucasian male developed end-stage liver
failure due to HCV genotype 1b infection and received
LT for a first time in 2007. Recurrent hepatitis C was
documented in 2008 (Metavir score A2F1) and treated
with pegylated interferon-α (PEG-IFN-α) and RBV, with
a null response. Advanced fibrosis (Metavir score A2F3)
was documented in 2011. Incipient graft failure and
right retinal detachment subsequently precluded IFN-
based antiviral therapy. Progressive graft failure was
noted toward the end of 2012. At no point there was
any evidence of allograft rejection. In September 2013,
the Child-Pugh score increased to C10 and model for
end-stage liver disease (MELD) score to 26, with jaun-
dice, ascites, edema and profound fatigue. Total bilirubin
was 229 μmol/l, albumin 29 g/l, prothrombin time 41%,
INR 1.6, and serum creatinine 140 μmol/l. Immunosup-
pressive treatment consisted of cyclosporine 50 mg bid
(with trough levels around 80 μg/l) and prednisone 5 mg
qd. Multidisciplinary team discussion concluded to list-
ing of the patient for re-transplantation provided that he
could benefit from effective antiviral therapy before his
second LT.
SOF was provided by Gilead Sciences Inc. (Foster City,
CA) on a compassionate use basis and was started at aFigure 1 Evolution of HCV RNA and MELD score in a 54-year-old pati
(SOF) and ribavirin (RBV) prior to liver re-transplantation. Despite the
severely decompensated and liver re-transplantation was performed in Jan
liver re-transplantation and remained undetectable on follow-up througho
Re-LT, liver re-transplantation.dose of 400 mg qd at the beginning of November 2013.
Given the impaired renal function, RBV was started 3
weeks prior to SOF to ensure tolerability and pursued
thereafter at a daily dose of 400-600 mg. As shown in
Figure 1, HCV RNA declined rapidly upon the introduc-
tion of SOF and became undetectable 3 weeks later.
Treatment was well tolerated and there was no need for
the administration of erythropoietin.
The results of therapeutic drug monitoring (TDM) for
SOF, RBV and cyclosporine are shown in Table 1. Details
of the methodology developed to measure plasma concen-
trations of SOF, based on liquid chromatography coupled
with tandem mass spectrometry, will be reported elsewhere
(LAD, unpublished data). RBV plasma concentrations were
determined using a previously described analytical method
[14]. Cyclosporine trough levels were determined by
enzyme multiplied immunoassay on a Cobas Integra® 400
plus system using reagents from Roche Diagnostics
(Rotkreuz, Switzerland).
As shown in Table 1, SOF was measurable in the ng/
ml concentration range in some of the plasma samples
obtained 24 hours after drug administration. RBV con-
centrations reached a steady state between 2000 and
2500 ng/ml after around 4 weeks. Doses of cyclosporine
had to be reduced by 25% in the last weeks before re-
transplantation likely due to progressive liver dysfunction.
As shown in Figure 1, liver function continued to deteri-
orate despite the virological response, with an increase of
the MELD score to 29. Therefore, re-transplantation was
performed in January 2014, after a total of 66 days on SOF
and 46 days of undetectable serum HCV RNA. SOF and
RBV were both discontinued at re-transplantation.ent with end-stage recurrent hepatitis C treated with sofosbuvir
rapid virological response to SOF and RBV, the recipient remained
uary 2014. HCV RNA was undetectable in serum for 46 days prior to
ut January 2015 (i.e. more than 1 year post-liver re-transplantation).
Table 1 Therapeutic drug monitoring and selected laboratory values
Tx
wk
RBV dose
(mg)
RBV level
(ng/ml)
SOF dose
(mg)
SOF level
(ng/ml)
CsA dose
(mg)
CsA level
(μg/l)
Creat.
(μmol/l)
INR Total bilirubin
(μmol/l)
HCV RNA
(log IU/ml)
−3 - ND - - 50-50 79 124 1.5 119 5.9
−1 400 873 - - 50-50 77 121 1.7 102 6.0
0 400 1253 - - 50-50 69 118 1.6 101 5.8
1 600 1453 400 ND 50-50 67 132 1.7 102 2.6
2 600 2161 400 0.7 50-50 83 113 1.7 118 <1.2 (traces)
3 600 2234 400 ND 50-50 91 138 1.7 103 ND
4 400 2457 400 0.8 50-50 86 160 1.8 168 ND
5 400 1968 400 NA 50-50 103 133 1.8 83 ND
6 400 2789 400 1.9 50-25 81 173 2.0 106 ND
8 400 2594 400 ND 50-25 63 203 1.9 129 ND
10 400 2231 400 ND 50-25 79 188 1.6 116 ND
Treatment weeks (Tx wk) relate to the start of sofosbuvir (SOF). Ribavirin (RBV) was started following the blood drawing on week -3 and SOF following the blood
drawing on week 0. Creat., creatinine; CsA, cyclosporine A; INR, international normalized ratio; NA, not available; ND, not detectable; RBV, ribavirin.
Vionnet et al. BMC Gastroenterology  (2015) 15:38 Page 3 of 4The postoperative course was uneventful and the pa-
tient returned home 4 weeks later. An episode of acute
cellular rejection (Banff 7) was treated with high-dose
corticosteroid boluses in March 2014. Liver function tests
have remained normal in the following and, most import-
antly, HCV RNA has remained undetectable throughout
the entire postoperative course until January 2015, i.e. more
than 1 year after re-transplantation.
Discussion
The management of recurrent HCV infection after LT
represented a major challenge until recently. PEG-IFN-α
and RBV combination therapy has limited efficacy and is
difficult to manage [1-3]. Tolerability remained generally
poor and there were significant drug-drug interactions
with triple therapy comprising the first-generation NS3-
4A protease inhibitors telaprevir or boceprevir [15,16].
However, outcomes have improved greatly with the ad-
vent of new DAAs and IFN-free combination therapies
[8,9,12,13]. More importantly, these new therapeutic op-
tions also offer opportunities to treat HCV infection prior
to LT and to prevent re-infection of the graft. In this con-
text, Curry et al. recently reported the successful use of
SOF and RBV in a series of patients with compensated cir-
rhosis awaiting a first LT for HCV-related hepatocellular
carcinoma [10]. The authors found that HCV RNA nega-
tivity in serum for at least 30 days prior to LT prevented
HCV re-infection in the majority of patients.
We report here the first case to our knowledge of suc-
cessful SOF and RBV treatment before re-transplantation
of a patient with graft failure due to recurrent hepatitis C,
with a previous null response to PEG-IFN-α and RBV com-
bination therapy. Antiviral therapy was well tolerated and
resulted in undetectable HCV RNA in serum within 3
weeks. Despite this rapid and complete virological response,
liver function continued to deteriorate. This is consistentwith a recent report on the use of SOF plus daclatasvir
for post-transplant recurrent hepatitis C in which there
was a lack of clinical benefit when treatment was given
late [17]. Liver re-transplantation was performed after 46
days of undetectable HCV RNA, without re-infection of
the second graft.
TDM of SOF, RBV and cyclosporine demonstrated the
absence of excessive accumulation of any of these drugs
in our patient.
SOF is a prodrug with short half-life (about 0.4 h) and
rapid uptake into hepatocytes, followed by phosphorylation
to the active triphosphate derivative. While the inactive me-
tabolite GS-331007 accounts for > 90%, SOF itself accounts
for only about 4% of the systemic exposure. Hence, the low
but still measurable SOF trough plasma concentrations ob-
served at some time points period are consistent with an
increase in SOF exposure, expected with impaired liver and
renal function as well as the co-administration of cyclospor-
ine. Indeed, an average 143% increase in SOF area under
the curve (AUC) was described in patients with severe hep-
atic impairment [18] and an increase by 61 and 107% was
found in mild and moderate renal failure, respectively [19].
In addition, a 4.5-fold increase in SOF AUC was reported
in the context of concomitant cyclosporine administration
[20]. In our patient, impaired liver function, the administra-
tion of cyclosporine and mild to moderate renal impair-
ment likely explain a 6- to 8-fold increase in SOF exposure,
consistent with plasma concentrations that are still measur-
able 24 hours after drug administration. However, no dose
adjustment was required in our patient. As reported previ-
ously, SOF exposure had no significant impact on cyclo-
sporine levels [20].
Conclusion
This observation illustrates the successful and safe treat-
ment with SOF and RBV in a patient with decompensated
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of re-infection after re-transplantation. This regimen was
well tolerated even in the setting of liver graft failure
with chronic renal insufficiency and immunosuppres-
sive drug therapy. The use of DAAs may allow liver re-
transplantation for recipients who remain decompensated
despite negativation of serum HCV RNA. These DAAs are
likely to improve the outcome of liver re-transplantation
for end-stage recurrent hepatitis C.
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